Rapport Therapeutics CEO Abraham Ceesay disposes of USD 87,135.01 in common shares
Bitget2026/09/24 20:05- Rapport Therapeutics CEO Abraham Ceesay sold 2,210 common shares on Sept. 23, 2026.
- Sales priced at USD 39.0523, USD 39.8602, USD 41.05.
- Directly held stake fell to 456,767 shares following the transactions.
- Form also reported 81,729 shares held indirectly via the Ceesay Family Irrevocable Trust.
- It also reported 20,729 shares held indirectly via the Dorothy Ceesay Irrevocable Trust.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
enGene interim CMO William Grossman acquires common shares worth $10,050.94
VUG ETF Climbs 0.2%
Rollins Inc. Stock Slips 6.4%, Underperforms Market
Meta launches AI-powered game development tool, competitor stocks drop in response
At the Connect conference, Meta launched two AI game creation tools, Horizon Create and Horizon Studio, allowing users to generate complete 2D/3D games—including level design and multiplayer features—simply through text descriptions, and directly distribute them to platforms such as Facebook and Instagram. The news led to a 4.5% increase in Meta’s stock price, while gaming stocks Roblox and Unity Software saw declines of up to 4.1% and 6.9%, respectively.